제한기 소세포폐암 치료: 타를라타맙과 듀르발루맙 병합 vs. 듀르발루맙 단독

Eligible participants with limited stage-small cell lung cancer (LS-SCLC) will be enrolled after completion of chemotherapy and radiation. Participants will be randomized to either tarlatamab in combination with durvalumab or durvalumab alone as consolidation therapy. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent. Tarlatamab is a targeted cancer treatment. It works by acting as a matchmaker between the immune system's T-cells and the cancer cells, forcing them to come together so the T-cells can attack the cancer. Image testing will be done standardly during treatment. These tests show whether the cancer has progressed and if further treatment may be needed. The purpose of this trial is to evaluate how well the treatment works (how long before your cancer comes back and how long you live).